2013
LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitors
2011
Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13
Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I. Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal Of Child And Adolescent Psychopharmacology 2011, 21: 555-564. PMID: 22070180, PMCID: PMC3279715, DOI: 10.1089/cap.2010.0134.Peer-Reviewed Original ResearchConceptsMedication-free subjectsEpidermal growth factorHealthy controlsInflammatory markersIL-13IL-1 receptor antagonistGrowth factorSerum inflammatory markersChemoattractant protein-1Placebo groupClinical improvementBaseline visitIL-17Serum levelsCytokine concentrationsInflammatory moleculesSerum concentrationsClinical trialsHealthy subjectsIL-1Interleukin-13RisperidoneAltered levelsProtein 1Diagnosis of autism
2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitorsAdulthood Outcome of Tic and Obsessive-Compulsive Symptom Severity in Children With Tourette Syndrome
Bloch MH, Peterson BS, Scahill L, Otka J, Katsovich L, Zhang H, Leckman JF. Adulthood Outcome of Tic and Obsessive-Compulsive Symptom Severity in Children With Tourette Syndrome. JAMA Pediatrics 2006, 160: 65-69. PMID: 16389213, PMCID: PMC2291298, DOI: 10.1001/archpedi.160.1.65.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic alpha-AgonistsAdultAntipsychotic AgentsAttention Deficit Disorder with HyperactivityBipolar DisorderChildDepressive DisorderFemaleFollow-Up StudiesHumansIntelligence TestsMaleObsessive-Compulsive DisorderProspective StudiesSchizophreniaSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexTic DisordersTourette SyndromeConceptsTic symptomsTourette syndromeTic severitySymptom severityObsessive-compulsive disorderBaseline clinical measurementsChildhood-onset neuropsychiatric disorderOCD symptomsPercent of patientsProspective cohort studyPercent of subjectsOutpatient specialty clinicsThird of childrenThird of adultsAge 14 yearsStructured clinical evaluationCohort studyClinical courseComplete resolutionClinical evaluationPhonic ticsSpecialty clinicFollow-up interviewObsessive-compulsive symptom severityAverage age
2005
Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone
Scahill L, Blair J, Leckman JF, Martin A. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. Journal Of Psychopharmacology 2005, 19: 205-206. PMID: 15728441, DOI: 10.1177/0269881105049042.Peer-Reviewed Original Research
2003
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60: 1130-1135. PMID: 12682319, DOI: 10.1212/01.wnl.0000055434.39968.67.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBody WeightChildDiagnostic Techniques, NeurologicalDopamine AntagonistsDose-Response Relationship, DrugDouble-Blind MethodErectile DysfunctionFemaleHeart Conduction SystemHumansMaleMiddle AgedPhobic DisordersRisperidoneSeverity of Illness IndexTicsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScalePlacebo-controlled trialTotal tic scoreTourette syndromeTic scoreYGTSS total tic scoreCardiac conduction timesSafety of risperidonePrimary outcome measureWeeks of treatmentDurability of efficacyTic Severity ScaleShort-term treatmentMedication-free subjectsPlacebo patientsMedication discontinuationRisperidone groupExtrapyramidal symptomsTic symptomsOutcome measuresDose reductionConduction timeSeverity ScaleTic severityBody weight
2000
Risperidone-Associated Weight Gain in Children and Adolescents: A Retrospective Chart Review
Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF. Risperidone-Associated Weight Gain in Children and Adolescents: A Retrospective Chart Review. Journal Of Child And Adolescent Psychopharmacology 2000, 10: 259-268. PMID: 11191686, DOI: 10.1089/cap.2000.10.259.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsBody Mass IndexChildFemaleHumansMaleRetrospective StudiesRisperidoneSex CharacteristicsWeight GainConceptsBody mass indexSignificant weight gainBaseline weightRisperidone useWeight gainStandardized z-scoresZ-scoreConcomitant medication useRisperidone-treated subjectsWeight changeRetrospective chart reviewSmall case seriesPsychiatric inpatient populationProportion of subjectsSubstantial weight gainRisperidone dosageNeuroleptic exposureChart reviewMedication useMonths of observationCase seriesMass indexInpatient populationWeight increaseTanner staging
1992
Tourette's syndrome
Leckman JF. Tourette's syndrome. New Directions For Student Leadership 1992, 1992: 29-33. PMID: 1352621, DOI: 10.1002/yd.23319925407.Peer-Reviewed Original Research
1987
Drug treatment of obsessive-compulsive disorder: a review of findings in the light of diagnostic and metric limitations.
Towbin KE, Leckman JF, Cohen DJ. Drug treatment of obsessive-compulsive disorder: a review of findings in the light of diagnostic and metric limitations. Psychiatric Developments 1987, 5: 25-50. PMID: 2885832.Peer-Reviewed Original Research
1986
Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins.
Price R, Leckman J, Pauls D, Cohen D, Kidd K. Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins. Neurology 1986, 36: 232-7. PMID: 2868428, DOI: 10.1212/wnl.36.2.232.Peer-Reviewed Original Research